Semaglutide Has Disproportionate Suicidality Signal, Analysis Finds​Semaglutide Has Disproportionate Suicidality Signal, Analysis Finds 

(MedPage Today) — A disproportionality analysis based on reports in a World Health Organization (WHO) database suggested a suicidal ideation signal with the GLP-1 receptor agonist semaglutide (Ozempic, Rybelsus, Wegovy). Between 2000 and 2023… ​ (MedPage Today) — A disproportionality analysis based on reports in a World Health Organization (WHO) database suggested a suicidal ideation Read More

Zepbound Can Prevent Diabetes; Menopause and Cognition; Tandem’s Insulin Pump Update​Zepbound Can Prevent Diabetes; Menopause and Cognition; Tandem’s Insulin Pump Update 

(MedPage Today) — In a phase III study of adults with pre-diabetes and obesity or overweight, tirzepatide (Zepbound) reduced the risk of developing type 2 diabetes by 94% over a 3-year period, Eli Lilly announced. In related news, real-world… ​ (MedPage Today) — In a phase III study of adults with pre-diabetes and obesity or Read More

Mounjaro, Zepbound cut odds for diabetes by 94% in at-risk people, study finds​Mounjaro, Zepbound cut odds for diabetes by 94% in at-risk people, study finds 

Tirzepatide, the blockbuster GLP-1 medicine known as Mounjaro for diabetes and Zepbound for weight loss, cut the odds that an obese, prediabetic person will develop diabetes by 94%, a new trial shows. ​Tirzepatide, the blockbuster GLP-1 medicine known as Mounjaro for diabetes and Zepbound for weight loss, cut the odds that an obese, prediabetic person Read More

Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Type 2 Diabetes​Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Type 2 Diabetes 

This cohort study investigates the risks of mortality and adverse cardiovascular and kidney outcomes among individuals with type 2 diabetes taking tirzepatide vs glucagon-like peptide 1 receptor agonists. ​This cohort study investigates the risks of mortality and adverse cardiovascular and kidney outcomes among individuals with type 2 diabetes taking tirzepatide vs glucagon-like peptide 1 receptor Read More

Popularity of Ozempic and Wegovy among privately insured patients may worsen disparities, suggests study​Popularity of Ozempic and Wegovy among privately insured patients may worsen disparities, suggests study 

A USC study suggests that publicly insured individuals who are most likely to benefit from new drugs for diabetes and obesity are less likely to get them than those with private insurance. ​A USC study suggests that publicly insured individuals who are most likely to benefit from new drugs for diabetes and obesity are less Read More

Safety and Risk Assessment of No-Prescription Online Semaglutide Purchases​Safety and Risk Assessment of No-Prescription Online Semaglutide Purchases 

This qualitative study assesses the quality, amount of active ingredient, and characteristics associated with counterfeiting of semaglutide purchased from illegal online pharmacies without a prescription. ​This qualitative study assesses the quality, amount of active ingredient, and characteristics associated with counterfeiting of semaglutide purchased from illegal online pharmacies without a prescription.